Evotec Overview
- Year Founded
-
1993
- Status
-
Public
- Employees
-
5,022
- Stock Symbol
-
EVT
- Investments
-
67
- Share Price
-
$6.88
- (As of Friday Closing)
Evotec General Information
Description
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.
Contact Information
Website
www.evotec.comCorporate Office
- Essener Bogen 7
- 22419 Hamburg
- Germany
Corporate Office
- Essener Bogen 7
- 22419 Hamburg
- Germany
Evotec Stock Performance
As of 14-Mar-2025, Evotec’s stock price is $6.88. Its current market cap is $1.22B.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $6.88 | $6.76 | $5.53 - $15.97 | $1.22B | 863K | -$1.05 |
Evotec Financials Summary
As of 30-Sep-2024, Evotec has a trailing 12-month revenue of $843M.
|
In Thousands, USD |
TTM 30-Sep-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | 1,450,237 | 4,140,225 | 2,547,319 | 8,453,787 |
| Revenue | 842,671 | 845,562 | 790,075 | 730,701 |
| EBITDA | (212,094) | 16,082 | (69,337) | 371,669 |
| Net Income | (185,841) | (90,800) | (184,684) | 254,797 |
| Total Assets | 2,223,523 | 2,489,878 | 2,420,666 | 2,530,696 |
| Total Debt | 524,997 | 692,200 | 543,356 | 580,735 |
Evotec Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Evotec Comparisons
Industry
Financing
Details
Evotec Competitors (44)
One of Evotec’s 44 competitors is Novartis, a Corporation company based in Basel, Switzerland.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Novartis | Corporation | Basel, Switzerland | ||||
| VBI Vaccines | Private Debt Financed | Cambridge, MA | ||||
| Astellas Pharma | Corporation | Tokyo, Japan | ||||
| Merck & Co. | Corporation | Rahway, NJ | ||||
| Immatics | Formerly VC-backed | Tuebingen, Germany |
Evotec Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Evotec Patents
Evotec Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20190062423-A1 | Methods for reduction of pathological fibrosis and associated disorders and diseases | Inactive | 04-Sep-2015 | ||
| EP-3344260-A2 | Modulation of gpr124 for reduction of pathological fibrosis | Inactive | 04-Sep-2015 | ||
| US-20210403554-A1 | Methods for reduction of pathological fibrosis and associated disorders and diseases | Inactive | 04-Sep-2015 | ||
| ES-2720577-T3 | Bicyclic tetrahydrotiazepine derivatives useful for the treatment of neoplastic and / or infectious diseases | Active | 02-Mar-2015 | ||
| US-20180170888-A1 | Bicyclic tetrahydrothiazepine derivatives useful for the treatment of neoplastic and/or infectious diseases | Active | 02-Mar-2015 | C07D285/36 |
Evotec Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Evotec Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Evotec Investments & Acquisitions (67)
Evotec’s most recent deal was a Later Stage VC with Aeovian Pharmaceuticals for . The deal was made on 13-May-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Aeovian Pharmaceuticals | 13-May-2024 | Later Stage VC | Drug Discovery | ||
| Tubulis | 14-Mar-2024 | Later Stage VC | Drug Discovery | ||
| NephThera | 01-Jul-2023 | Merger/Acquisition | Drug Discovery | ||
| Cajal Neuroscience | 29-Nov-2022 | Early Stage VC | Drug Discovery | ||
| Central Glass Germany | 01-Nov-2022 | Merger/Acquisition | Specialty Chemicals |
Evotec ESG
Risk Overview
Risk Rating
Updated February, 13, 2025
18.83 | Low Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,946
Rank
Percentile
Pharmaceuticals
Industry
of 847
Rank
Percentile
Laboratory Equipment and Services
Subindustry
of 60
Rank
Percentile
Evotec Exits (8)
Evotec’s most recent exit was on 27-Apr-2021 from Exscientia. The exit was categorized as with 13 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Exscientia | 27-Apr-2021 | Completed |
|
||
| OxVax | 21-Apr-2021 | Completed |
|
||
| Curexsys | 14-Dec-2020 | Completed |
|
||
| Pancella | 02-Apr-2020 | Completed |
|
||
| Lab10x | 24-Jun-2019 | Joint Venture | Completed |
|
Evotec Affiliates
Subsidiaries (12)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Evotec Gt | Vienna, Austria | 2019 | |
| Sanofi (Toulouse Operations) | Paris, France | 2014 | |
| Evotec Id (Lyon) | Lyon, France | 2014 | |
| Just - Evotec Biologics | Seattle, WA | 2014 | |
| Rigenerand | Medolla, Italy | 2009 |
Evotec FAQs
-
When was Evotec founded?
Evotec was founded in 1993.
-
Where is Evotec headquartered?
Evotec is headquartered in Hamburg, Germany.
-
What is the size of Evotec?
Evotec has 5,022 total employees.
-
What industry is Evotec in?
Evotec’s primary industry is Drug Discovery.
-
Is Evotec a private or public company?
Evotec is a Public company.
-
What is Evotec’s stock symbol?
The ticker symbol for Evotec is EVT.
-
What is the current stock price of Evotec?
As of 14-Mar-2025 the stock price of Evotec is $6.88.
-
What is the current market cap of Evotec?
The current market capitalization of Evotec is $1.22B.
-
What is Evotec’s current revenue?
The trailing twelve month revenue for Evotec is $843M.
-
Who are Evotec’s competitors?
Novartis, VBI Vaccines, Astellas Pharma, Merck & Co., and Immatics are some of the 44 competitors of Evotec.
-
What is Evotec’s annual earnings per share (EPS)?
Evotec’s EPS for 12 months was -$1.05.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
